Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Romiplostim - Amgen

Next Previous
Drug Profile

Romiplostim - Amgen

Alternative Names: AMG-531; Nplate; Romiplate

Latest Information Update: 31 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Kirin-Amgen
  • Class Antianaemics; Carrier proteins; Immunotherapies; Radioprotectives; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura; Radiation injuries; Thrombocytopenia; Aplastic anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute radiation syndrome; Aplastic anaemia; Idiopathic thrombocytopenic purpura
  • Phase III Thrombocytopenia
  • Phase I/II Myelodysplastic syndromes

Most Recent Events

  • 04 Aug 2026 Phase-III clinical trials in Idiopathic thrombocytopenic purpura (Treatment-naive, Combination therapy) (SC) (NCT07700238)
  • 13 Jul 2026 Amgen plans a phase III ROMISTER trial for Idiopathic thrombocytopenic purpura (Combination therapy, Treatment naive) (SC) in July 2027 (NCT07700238)
  • 30 Sep 2025 Regulatory submission withdrawn for Aplastic anaemia in Taiwan (SC) (Kyowa Kirin pipeline, September 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top